A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry
about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignThe hepatitis C virus glycan shield and evasion of the humoral immune responseNeutralizing antibody response to hepatitis C virusThe Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope ProteinHepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and NeutralizationCharacterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C VirusExpression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 BindingA Point Mutation Leading to Hepatitis C Virus Escape from Neutralization by a Monoclonal Antibody to a Conserved Conformational EpitopeIdentification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing AntibodiesMutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entryThe Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the MoleculeIdentification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virusStructural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization EscapeDiscrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralizationCD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cellsHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateNaturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralizationAdaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry.Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a InfectionPrediction of linear B-cell epitopes of hepatitis C virus for vaccine developmentA Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable RegionBroadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein boosterHepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new hostHepatitis C virus utilizes VLDLR as a novel entry pathway.Hepatitis C virus entry.Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.CD81 and hepatitis C virus (HCV) infection.Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.The past, present and future of neutralizing antibodies for hepatitis C virus.
P2860
Q26801759-8E56F58D-D221-45AA-ADC3-A1786E338359Q27023390-99AC25DE-93E7-4A34-AED2-185C1C9A09D2Q27027484-AC6FD146-FD6E-4FCB-9916-7720F413CEFDQ27481009-8443E0C3-780F-48A5-A21F-EC53ACE34CD5Q27481012-D34094D5-1846-4841-8DE6-C559A03DF697Q27481024-855C6717-D2EE-48F6-9A1A-E6783519C815Q27481026-1A75C919-9B88-4A39-9A9D-F414EA364194Q27486113-50FC8D4E-C748-401D-87A7-FC7BA2FA1883Q27487399-E0CF7B81-630B-4534-BDAD-C6DDD06F5FA9Q27489898-359D77DC-7E3C-42CF-B408-9D9658155B4BQ27490948-18688F82-2A14-4A23-B213-49576CFE80B3Q27666330-0B09B3E5-8CEF-4977-8472-467E2C19BC8CQ27677400-7F91FF05-8607-4434-A946-A20DA6BCF20EQ27678252-9EB64B1D-0F1D-42C8-8879-996F3F32C848Q27684579-10EADD65-669B-42B0-892B-0534B889D443Q28114859-7EDC95EA-3E92-4F4E-B92B-BF1994F693E3Q28482261-DBE1FCA4-9B95-4E1B-9C9D-5D6859B40103Q28731355-55D169B3-6FD2-414A-A568-1CD3A12F4543Q33628805-6932F6A5-EE4F-47F1-9BDE-06E436823478Q33648339-DCACD65F-A2A3-46DA-A50D-88437C546C7DQ33913588-EDB4AC41-E2EA-45F7-B04F-92DF3C8FBC24Q34262165-92D8E366-9D0B-407A-AF44-4F4F4A9A98E8Q35076885-E8B20A4D-AE24-4610-840C-63B0E0580AD5Q35213305-A440FECA-920B-44B8-BEAD-1AD8B47F58B0Q35274913-DE875449-3758-4F1C-9187-3F0C91703853Q35630492-F8D00E1E-39AE-4360-9ADF-77983D0B706BQ35872361-27C3A576-5756-45A1-8DEC-CF557ED055B0Q36133495-D9FA38AA-2631-4D52-ABD0-5C579EEBEB20Q36334312-D8F5F7E2-09FD-4F68-814A-8F8C1448A973Q36363203-ED93EA75-D897-4207-8A1F-B680E743C492Q36363966-97E3FB37-1E28-4E9E-8921-6F7AF6B37AA1Q36459392-628005E2-D9BB-4AD4-981B-381989DA4D8FQ36946317-605587E7-B069-4615-9B32-F6F4148FA358Q36956517-09BBB9A3-6573-45A4-8752-C418CF92E381Q37439266-F2DDE735-E584-4950-AC4B-692510ED4BE7Q37609487-5F01CA34-B91D-4FCA-8510-FCDEBACD00C2Q37611819-4E84F0CF-EBB7-4A4F-AD0B-EBB1E65D2F01Q37629584-F4304F69-92EF-4D04-B710-727BAFC4B141Q38128299-EF42EC0F-E20D-4C16-86AC-8FC14425005DQ38192357-3574A7B3-F751-452E-BDED-9D2FD49D273E
P2860
A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@ast
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@en
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@nl
type
label
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@ast
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@en
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@nl
prefLabel
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@ast
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@en
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@nl
P2093
P2860
P356
P1433
P1476
A Conserved Gly436-Trp-Leu-Ala ...... f CD81 Binding and Viral Entry
@en
P2093
Anne L Maerz
Pantelis Poumbourios
P2860
P304
P356
10.1128/JVI.00029-06
P577
2006-08-01T00:00:00Z